TrialNature medicine2023

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.

Leili Gao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.